Poster Presentation on MCY-M11 at ASCO 2020
Released : May 14, 2020 07:00
("MaxCyte" or the "Company")
MaxCyte to Present Poster Presentation on MCY-M11
at ASCO 2020 Annual Meeting
The Poster Discussion presentation, entitled Feasibility and preliminary safety and efficacy of first-in-human intraperitoneal delivery of MCY-M11, anti-human-mesothelin CAR mRNA transfected into peripheral blood mononuclear cells, for ovarian cancer and malignant peritoneal mesothelioma, will be available in the Developmental Therapeutics: Immunotherapy session, which can be accessed on demand beginning at 8 a.m. ET on Friday, May 29, 2020.
MCY-M11 is a wholly-owned, non-viral, mRNA-based cell therapy candidate manufactured using un-manipulated peripheral blood mononuclear cells. It is under development for the treatment of ovarian cancer and peritoneal mesothelioma. The ongoing study so far demonstrates both the safety and of MCY-M11 as well as the feasibility of one-day manufacturing and intraperitoneal delivery of our cell product.
As previously announced, dosing began in October 2019 in the third cohort in MaxCyte's Phase I dose-escalation trial with MCY-M11 and there have been no dose-limiting toxicities or related serious adverse events observed in the three completed cohorts. A fourth dosing cohort commenced in March 2020 as expected. Preliminary clinical results for the trial are expected to be announced in H2 2020. Clinical development of MCY-M11 continues now under the auspices of MaxCyte's subsidiary CARMA Cell Therapies™. No new material information will be included in the ASCO presentation.
For more information about the ASCO20 Virtual Scientific Program and a link to the abstract, please visit:
About CARMA Cell Therapies
Through its wholly owned subsidiary, CARMA Cell Therapies, MaxCyte is facilitating advancement of novel mRNA-based cell therapies for cancer and other diseases with serious unmet needs. MaxCyte has developed CARMA, a novel and proprietary platform for the development of non-viral, human messenger RNA (mRNA)-based, chimeric antigen receptor (CAR) or T-cell receptor (TCR) redirected immune cell therapies. CARMA [derived from CAR mRNA] utilizes MaxCyte's Flow Electroporation® technology for highly efficient, non-viral, delivery of one or more mRNA(s) into un-manipulated peripheral blood mononuclear cells (PBMCs) or isolated immune cells such as T- or NK-cells. CARMA offers the potential for a safer cell therapy, as a result of transient expression of receptor(s) and a non-viral delivery approach. Together, CARMA and MaxCyte's EXPERT® family of instruments also offer the potential for a significantly streamlined, scalable, and cost-effective GMP manufacturing process without the complexity of virus-based products. At the start of 2020, MaxCyte established CARMA Cell Therapies as a wholly owned subsidiary to facilitate independent investment and new partnerships to advance the CARMA platform. MaxCyte has retained Locust Walk, a global life science strategic advisory and transaction firm. The Company expects CARMA to be self-funded by end of 2020. For more information, visit https://www.maxcyte.com/carma-cell-therapies/.
MaxCyte is a clinical-stage global cell-based therapies and life sciences company. As the inventors of the premier cell-engineering enabling technology, the Company helps bring the promise of next-generation cell and gene-editing therapies to life. The Company's technology is currently being deployed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte licences have been granted for more than 100 cell therapy programmes, with more than 70 licensed for clinical use, and the Company has now entered into ten clinical/commercial license agreements with leading cell therapy and gene editing developers. MaxCyte was founded in 1998, is listed on the London Stock Exchange (AIM:MXCT) and is headquartered in
For further information, please contact:
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the